SGI-110 to potentiate platinum response: A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

Trial Profile

SGI-110 to potentiate platinum response: A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Guadecitabine (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms SPIRE
  • Most Recent Events

    • 08 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.
    • 03 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top